The DOI matches its Crossref record.
INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS
Abstract
Initial studies utilizing cyclosporine (CsA)1 immunosuppression documented not only therapeutic efficacy (1), but also appreciable interindividual variation, both in clinical responses and in serum drug concentrations, in spite of fixed dosage regimens (2, 3). Optimal CsA schedules are difficult to establish: on the one hand, the therapeutic effect is not easily quantitated, both because of the absence of objective signs, such as blood pressure provides for antihypertensive agents, and because of the delayed time frame in which to detect rejection in the event of inadequate therapy, which results from the lack of suitable intermediate points with proved correlation with immunosuppression. On the other hand, CsA causes toxic side effects capable of increasing morbidity. Assuming that toxic levels of CsA exceed therapeutic levels, many physicians have routinely administered enough CsA to keep the patient nephrotoxic, in order to avert rejection. However, high initial doses of CsA appear to be associated with intractable nephrotoxicity and renal interstitial fibrosis (4). Indeed, as in theophylline, there appears—at least in some patients—to be an overlap of the concentration/response relationship for therapeutic and toxic effects, neither of which are clearly related to the administered dose. In other pharmacologic settings of a narrow therapeutic range, in part because of the lipophilic nature of the agent and its low apparent bioavailability, with toxic side effects upon overdosage and minimal effect upon underdosage, individualization of the drug regimen has achieved the specific goals of treatment. This overview addresses the question of whether therapeutic drug monitoring, pharmacokinetic analyses, and/or pharmacodynamic assessment of renal transplant recipients proffer criteria suitable for individualization of the CsA regimen, in order to afford prophylaxis of rejection episodes and minimize nephrotoxicity, thereby improving the risk: benefit ratio, obviating the variable outcome, and achieving uniform success of immunosuppressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oates, J. A., Wood, A. J. J., & Kahan, B. D. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212507 · Cited by 1,359
Self-citationFeutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Cyclosporin Clinical Pharmacokinetics
Fahr, A. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00004 · Cited by 356
First-pass metabolism of midazolam by the human intestine*
Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9 · Cited by 302
Dunn, C. J., Wagstaff, A. J., Perry, C. M., Plosker, G. L., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161130-00006 · Cited by 276
Metadata
- Authors
- KAHAN, B. D.
- Venue
- Transplantation
- Published
- 1985-11
- Volume
- 40
- Issue
- 5
- Pages
- 457-476
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2008523006
- Cited by
- 269
- References
- 0
- FWCI
- 18.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. https://app.cochat.ai/papers/10.1097/00007890-198511000-00001
- The paper
- KAHAN, B. D. (1985). INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. Transplantation. https://doi.org/10.1097/00007890-198511000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.